Onco Actu du 12 novembre 2019

	2.6 ETIOLOGIE - ENVIRONNEMENT
5 Myths about Radon and Lung Cancer [Memorial Sloan Kettering Cancer Center] Radon is the second leading cause of lung cancer in the United States. People should be aware of their risk from radon exposure. Testing a home for radon is simple and inexpensive.
	3. PRÉVENTION
Shifting the Focus of Breast Cancer to Prevention [NY Times] If protective measures were widely adopted, they could significantly reduce women’s chances of ever getting breast cancer.
	3.1 PRÉVENTION - TABAC
Top Trump official suggests tobacco regulation distracts from FDA mission [STAT] Grogan’s comments on tobacco come as the administration has wavered on its attempts to ban some flavored vape products. They also follow two years in which Scott Gottlieb, Trump’s former FDA commissioner, made tobacco and nicotine product regulation a focus of his tenure at the agency.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
UK teen almost died from severe lung failure linked to vaping [New Scientist] Ewan Fisher, who turns 19 on Tuesday, ended up on life support. He was under age when he purchased vaping equipment over the counter from a shop and had been vaping for four to five months before he was taken ill aged 16.
Vaping Illnesses Are Linked to Vitamin E Acetate, C.D.C. Says [NY Times] Samples of lung fluid from patients with the mysterious illness led to a breakthrough in finding a possible cause. More than 2,000 people have been sickened, many from illicit marijuana-based products.
U.S. CDC reports 'breakthrough' in vaping lung injury probe as cases top 2,000 [Reuters] The discovery of Vitamin E acetate in lung samples offers the first direct evidence of a link with the substance and vaping-related lung injuries. The substance has also been identified in tests by U.S. and state officials of product samples collected from patients with the vaping injury.
Trump to meet with vaping industry as he mulls tighter regulation [Reuters] Trump did not give a time for the meeting or offer any other details. He said on Friday that his administration would come out with “an important position” on vaping this week.
US officials identify ‘strong culprit’ in vaping illnesses [AP] Vitamin E acetate has only recently been used as a thickener in vaping fluid, particularly in black market vape cartridges.
	4.12 BIOPSIES LIQUIDES
Illumina Unveils Liquid Biopsy Version of TSO 500 Panel, Highlights Early User Validations [Genome Web] Illumina this week announced the release of a new version of its TruSight Oncology 500 assay, designed for use with circulating tumor DNA in liquid biopsy testing. Two researchers who have had early access to the new panel shared their experience in a sponsored session at the annual meeting of the Association for Molecular Pathology on Thursday.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Glutamine-Blocking Drug Slows Tumor Growth And Strengthens Anti-Tumor Response [Johns Hopkins] Potentially, tumors that develop metabolic pathways to avoid the impacts of JHU083 could find themselves in a “blind alley,” said Powell. “By adding an additional metabolic antagonist, you could potentially get rid of the resistant tumors as well.”
	5.10 TRAITEMENTS - ESSAIS
Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer [ESMO] The results of the AcSé phase II study.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Cancer patient is first in Wales to get gene treatment [BBC News] Parts of the immune system - white blood cells called T-cells - were removed from John's blood at the University Hospital of Wales in Cardiff on Monday. Later that afternoon they were sent by courier to Amsterdam, and were frozen in liquid nitrogen before being flown to a laboratory in California.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma [BMS] The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication.
Following a win for Bavencio, Pfizer and Merck KGaA continue PD-L1 losing streak [EndPoints] Almost two years ago Pfizer and Merck KGaA conceded that their PD-L1 drug failed to significantly improve overall survival for gastric cancer patients in the third-line setting. We now know that Bavencio doesn’t work as a first-line maintenance therapy, either.
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer [EndPoints] The designation is for Opdivo (nivolumab) in combination with Yervoy (ipilimumab),  for treating advanced hepatocellular carcinoma (HCC), the most common form of liver cancer.
	5.12.9 IMMUNOTHÉRAPIES - SITC
Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors [Fierce Biotech] Bolt Biotherapeutics, founded by Engleman in 2015, plans to launch a clinical trial next year of its lead compound, which is part of a new class of cancer drugs called immune stimulating antibody conjugates (ISACs). The drug is a tumor-targeting antibody that’s connected to an agent that stimulates the immune system.
Nektar shows durability of Opdivo combo in 18-month update [Fierce Biotech] Nektar’s trial design means it is hard to tell whether NKTR-214 will live up to the promise seen by Zalevsky. In the absence of a comparator arm, it is unclear whether NKTR-214 is adding to the responses triggered by Opdivo.
NanoString Highlights the Results of Research Presented at the 2019 Annual Meeting of the Society of Immunotherapy for Cancer (SITC) [NanoString] Presentations Include Data from More than Thirty NanoString-Related Abstracts Including Five Using the GeoMx Digital Spatial Profiler.
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting [Nektar] New Data Presented for Previously Untreated Metastatic Melanoma Patients in PIVOT-02 Study of Bempegaldesleukin with Nivolumab.
SITC – the morning after the night before [Vantage] Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
The latest Cinderella story in oncology ends with a sudden rout as updated data display spooks investors [EndPoints] The focus at NextCure is centered on NC318, an antibody that is intended to shut down the immunosuppressive Siglec-15 — or S-15 — target.
	5.2 PHARMA
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia [AbbVie] Submission is based on positive results from the Phase 3 E1912 clinical trial, which showed significantly improved progression-free survival and overall survival in patients treated with IMBRUVICA plus rituximab, compared to the FCR chemoimmunotherapy regimen.
	5.2.6 PHARMA - BIOTECH
ASLAN Pharmaceuticals announces topline results from TreeTopp global pivotal study of varlitinib in biliary tract cancer [Aslan] Varlitinib did not meet the primary endpoints of progression-free survival (PFS) and overall response rate (ORR) as assessed by ICR according to RECIST. The safety findings were consistent with the known profile of varlitinib.
Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech [EndPoints] The results showed an improved response rate for Aslan’s varlitinib over the control arm, but not significantly.  The drug arm had a progression-free survival rate of 2.83 months compared to 2.79 in the control arm — basically a one-day difference.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
France to Maintain Fast Track Schemes for Clinical Trials [RAPS] As the new EU clinical trial regulation is expected to take effect next spring, France’s drug regulator, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), said it will maintain two fast tracks to speed clinical trials for new and already known medicinal products.
	6. LUTTE CONTRE LES CANCERS
Why NIH is beefing up its data sharing rules after 16 years [Science] Draft update to 2003 policy will require that all grantees make data sets freely available.
	6.11 PATIENTS
I Thought Being a Health Care Reporter Would Make Cancer Easier. I Was Wrong. [Politico] Nothing can prepare you for the immense number of complicated, sometimes life-or-death decisions the disease forces you to make about your own treatment.
	6.7 DMP, BIG DATA & APPLIS
Google Is Slurping Up Health Data—and It Looks Totally Legal [Wired] Tech giants can access all of your personal medical details under existing health privacy laws. The question is how else that data might get used.
Google signs healthcare data and cloud computing deal with Ascension [Reuters] Google and Ascension, which operates 150 hospitals and more than 50 senior living facilities across the United States, said the healthcare provider would move some data and analytics tools in its facilities to Google’s servers.
Google partners with major U.S. health system, gaining access to vast patient data in the process [STAT] The initiative, dubbed “Project Nightingale,” gives the tech giant the ability to analyze personal health information compiled by Ascension, a Catholic hospital system that operates in 21 states. It appears to be unusual in that it grants such a large amount of patient data to a third-party technology company without the knowledge of doctors or patients.